By David Ruohoniemi
Peer Reviewed
The obesity epidemic has been widely reported in recent years. In 2005, an estimated 23.2% of the world’s population was overweight and 9.8% were obese. …
Category: Class Act
Clinical Correlations
Are Opioids Effective in the Treatment of Chronic Low Back Pain?
April 17, 2019
By Anna Hirsch
Peer Reviewed
The use of opioid medications for chronic low back pain, or for any chronic non-cancer pain complaint, is still a source of controversy in …
Is There a Role for DOAC Level Monitoring in Clinical Practice?
April 9, 2019
By Thatcher Heumann, MD
Peer Reviewed
BackgroundÂ
Direct Oral Anticoagulants (DOACs) are a class of medications consisting of the thrombin inhibitor, dabigatran (Pradaxa), and the factor Xa inhibitors, rivaroxaban (Xarelto), apixaban (Eliquis), …
Pharmacists: The Optimal Solution to Suboptimal Vaccination Rates
April 5, 2019
By Nishanth Srivaths Iyengar, MD and David M. Oshinsky, MD
Peer Reviewed
Federal agencies such as the Centers for Disease Control and Prevention (CDC) publish exhaustive public health guidelines and …
Diagnostic Evaluation of Cryptogenic Stroke
April 2, 2019
Dixon Yang, MD
Peer Reviewed
Case and Introduction
A 52-year-old right-handed woman with hypertension is brought in by ambulance after her daughter notices a sudden onset of nonsensical speech and trouble walking. On exam, …
The History Behind Aspirin 81
February 22, 2019
By Joshua Novack
Peer Reviewed
Patients often come into clinics on a grocery list of medications. Common prescriptions include lisinopril 20 mg, amlodipine 2.5 mg, metformin 500 mg, and aspirin 81 mg. One …
The Fentanyl Crisis
February 15, 2019
By Andrew Segoshi
Peer Reviewed
If you live in New York, you’ve no doubt encountered the opioid epidemic sweeping the nation in the past decade. Whether it’s firsthand experience passing opioid users in the street congregating on St. Mark’s every summer, hearing …
Metformin’s Role in Type 1 Diabetes: the REMOVAL Trial
February 14, 2019
By William Plowe
Peer Reviewed
Metformin has been the first-line drug in type 2 diabetes for over a decade, but its possible benefit in type 1 diabetes (DM1) is still a matter of …